With its potential in R&D, big data presents endless opportunities for every stage of a drug's development. Pattern identification, predictive modeling and more efficient, diversified, criteria-based clinical trials are only some of the possibilities big data opens to pharma companies.
To reveal all the possibilities big data can offer to the pharma industry, Fleming Europe has organized the international Pharma Exabyte conference, taking place on 27 - 28 May 2015 in Berlin.
Together with the opportunities, this event will provide closer insight into the full integration of such capabilities, as they require operational and organizational transformations that most companies are still hesitant to implement. Furthermore, there is a very limited number of case studies available to learn from.
Over two days, the event will offer a broad scope of topics focused on big data. Expert speakers from CERN, Pfizer, AstraZeneca, Merck, Janssen, Novartis Vaccines, University of Cambridge and many other prestigious organizations will make presentations to attendees on perspectives from both industry and research institutes, and will introduce volume, velocity, variety and other 'V's.
Participants will have the opportunity to learn from focused case studies from various therapeutic areas, get inspired by the outside-the-box presentations incorporating the best practices of other industries, catch a glimpse into the future of medicine with "the Virtual Human" and much more!
The full event program may be downloaded here.
If you don't want your ideas to sit and gather dust, join Fleming Europe's Pharma Exabyte conference. You are also welcome to join the discussions in the Pharma R&D and Clinical Trials Forum.